Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 37.01%138.73B | -13.15%486.51B | -7.89%135.76B | -3.45%133.23B | -16.28%116.26B | -25.52%101.25B | 34.37%560.19B | 26.16%147.39B | 23.12%137.99B | 52.81%138.86B |
Cost of revenue | 22.90%61.82B | -0.27%240.48B | -3.73%66.13B | 16.77%65.85B | -1.39%58.2B | -11.79%50.3B | 33.23%241.13B | 35.94%68.69B | 19.40%56.39B | 44.43%59.02B |
Gross profit | 50.94%76.91B | -22.89%246.03B | -11.52%69.63B | -17.42%67.39B | -27.28%58.06B | -35.44%50.95B | 35.25%319.06B | 18.69%78.7B | 25.83%81.6B | 59.66%79.84B |
Operating expense | 24.26%45.58B | 8.61%164.4B | 24.79%50.11B | 0.44%40.56B | 0.95%37.06B | 7.46%36.68B | 24.92%151.37B | 23.12%40.15B | 29.07%40.38B | 28.09%36.71B |
Selling and administrative expenses | 23.41%45.54B | 4.55%158.96B | 1.72%41.19B | 0.20%40.61B | 8.82%40.26B | 8.46%36.9B | 25.52%152.04B | 23.98%40.49B | 29.07%40.53B | 28.46%37B |
-General and administrative expense | 23.41%45.54B | 4.55%158.96B | 1.72%41.19B | 0.20%40.61B | 8.82%40.26B | 8.46%36.9B | 25.52%152.04B | 23.98%40.49B | 29.07%40.53B | 28.46%37B |
Other operating expenses | 80.19%191M | 2,695.52%9.37B | 12,383.56%9.11B | -18.92%60M | 405.88%86M | -38.01%106M | -48.22%335M | 82.50%73M | 29.82%74M | -54.05%17M |
Total other operating income | -53.52%152M | 291.43%3.93B | -52.66%196M | -48.88%114M | 971.34%3.29B | 454.24%327M | 65.51%1B | 360.00%414M | 29.65%223M | 69.61%307M |
Operating profit | 119.53%31.33B | -51.32%81.63B | -49.34%19.53B | -34.92%26.83B | -51.31%21B | -68.14%14.27B | 46.15%167.69B | 14.41%38.55B | 22.81%41.22B | 102.02%43.13B |
Net non-operating interest income (expenses) | 146.25%605M | -196.51%-3.46B | -585.93%-926M | 83.95%-580M | -117.41%-644M | -136.00%-1.31B | 122.68%3.58B | -110.26%-135M | -809.82%-3.61B | 2,101.19%3.7B |
Non-operating interest income | 335.71%1.28B | -72.10%1.24B | 360.98%378M | 126.76%322M | -93.58%252M | -92.64%294M | 133.16%4.46B | -94.50%82M | -74.87%142M | 1,843.07%3.93B |
Non-operating interest expense | -57.80%676M | 437.37%4.7B | 500.92%1.3B | -75.98%902M | 294.71%896M | 346.24%1.6B | 188.78%875M | 24.71%217M | 6,605.36%3.76B | 567.65%227M |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | ||||||||||
Income before tax | 146.35%31.93B | -54.36%78.17B | -51.57%18.6B | -30.21%26.25B | -56.53%20.36B | -73.23%12.96B | 47.21%171.27B | 9.72%38.41B | 10.38%37.61B | 117.63%46.83B |
Income tax | 114.34%8.06B | -61.15%15.88B | -55.79%3.46B | -43.73%5.05B | -70.24%3.62B | -68.46%3.76B | 40.73%40.87B | -9.09%7.82B | 6.38%8.97B | 116.59%12.17B |
Net income | 159.43%23.87B | -52.23%62.29B | -50.49%15.15B | -25.97%21.21B | -51.72%16.74B | -74.79%9.2B | 49.37%130.4B | 15.85%30.59B | 11.69%28.65B | 117.99%34.67B |
Net income continuous operations | 159.43%23.87B | -52.23%62.29B | -50.49%15.15B | -25.97%21.21B | -51.72%16.74B | -74.79%9.2B | 49.37%130.4B | 15.85%30.59B | 11.69%28.65B | 117.99%34.67B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 159.43%23.87B | -52.23%62.29B | -50.49%15.15B | -25.97%21.21B | -51.72%16.74B | -74.79%9.2B | 49.37%130.4B | 15.85%30.59B | 11.69%28.65B | 117.99%34.67B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 159.43%23.87B | -52.23%62.29B | -50.49%15.15B | -25.97%21.21B | -51.72%16.74B | -74.79%9.2B | 49.37%130.4B | 15.85%30.59B | 11.69%28.65B | 117.99%34.67B |
Gross dividend payment | ||||||||||
Basic earnings per share | 159.06%32.35 | -51.56%84.45 | -50.67%20.52 | -25.79%28.74 | -50.49%22.69 | -74.00%12.4875 | 55.13%174.35 | 20.63%41.6 | 16.92%38.73 | 126.10%45.83 |
Diluted earnings per share | 159.24%32.25 | -51.54%84.16 | -50.64%20.45 | -25.75%28.66 | -50.49%22.62 | -73.99%12.44 | 55.33%173.68 | 20.76%41.43 | 17.05%38.6 | 126.41%45.69 |
Dividend per share | 0 | 1.48%34.25 | 2.86%18 | 0 | 0.00%16.25 | 0 | 12.50%33.75 | 0.00%17.5 | 0 | 30.00%16.25 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |